Targeted therapy of soft tissue sarcomas

Onkologie

Volumn 35, Issue SUPPL. 1, 2012, Pages 21-27

  Wardelmann, Eva ^a   Chemnitz, Jens M ^b   Wendtner, Clemens Martin ^b,c  

^a Institute of Pathology   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Klinikum Schwabing   (Germany)

Author keywords

Epigenetic mechanisms; GIST; Soft tissue sarcoma; Targeted therapy; VEGF

Indexed keywords

IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CARCINOGENESIS; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; SOFT TISSUE SARCOMA; TRANSLATIONAL RESEARCH;

DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS; SARCOMA;

EID: 84856456005     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/0003349587     Document Type: Article

References (56)

1. Wendtner CM, Delank S, Eich H: (Multimodality therapy concepts for soft tissue sarcomas). Internist (Berl) 2010;51:1388-96.
2. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA: Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007;8:513-24. (Pubitemid 46823060)
3. Lewis JJ, Leung D, Woodruff JM, Brennan MF: Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355-65. (Pubitemid 30191698)
4. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al.: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203. (Pubitemid 28041599)
5. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF: Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-89. (Pubitemid 26134227)
6. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al.: Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002; 359:2235-41. (Pubitemid 34717977)
7. Davis AM, O'Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, et al.: Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002; 20:4472-7. (Pubitemid 35334759)
8. Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al.: Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11:561-70.
9. No authors listed: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Metaanalysis Collaboration. Lancet 1997;350:1647-54.
10. Folpe AL, Kwiatkowski DJ: Perivascular epithelioid cell neoplasms: pathology and pathogenesis. Hum Pathol 2010;41:1-15.
11. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, et al.: Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006; 12:6920-8. (Pubitemid 44974484)
12. Stacchiotti S, Casali PG: Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep 2011;13:323-30.
13. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9. (Pubitemid 46621810)
14. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al.: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103. (Pubitemid 44275331)
15. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al.: Progression-free survival in gastrointestinal stromal tumours with highdose imatinib: randomised trial. Lancet 2004; 364:1127-34. (Pubitemid 39296599)
16. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, et al.: Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003;106:887-95. (Pubitemid 37071667)
17. Martin-Broto J, Gutierrez A, Garcia-del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande LM, et al.: Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 2010;21:1552-7.
18. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-25. (Pubitemid 41095223)
19. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA: Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-95. (Pubitemid 34747867)
20. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, Pauls K, Goldstein J, Hohenberger P, et al.: Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 2004;6:197-204. (Pubitemid 39136646)
21. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247-53.
22. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al.: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41:1751-7. (Pubitemid 41132637)
23. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38. (Pubitemid 44528723)
24. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104.
25. Joensuu H, Eriksson M, Hartmann J, Sundby Hall K, Schutte J, Reichardt A, Schlemmer M, et al.: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/ AIO). J Clin Oncol 2011;29(suppl):abstr LBA1.
26. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, et al.: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-73. (Pubitemid 46224187)
27. Blay JY: Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol 2011;22:280-7.
28. Friedrichs N, Trautmann M, Endl E, Sievers E, Kindler D, Wurst P, et al.: Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer 2011;129:1564-75.
29. Montaner S: Akt/TSC/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi's sarcoma. Cell Cycle 2007;6:438-43. (Pubitemid 46393447)
30. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al.: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140-51.
31. Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, et al.: Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008; 358:200-3.
32. No authors listed: Ridaforolimus. Drugs R D 2010;10:165-78.
33. Squillace RM, Miller D, Cookson M, Wardwell SD, Moran L, Clapham D, et al.: Antitumor activity of ridaforolimus and potential cell cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther 2011;10:1959-68.
34. Chawla SP, Blay J, Ray-Coquard IL, Le Cesne A, Staddon AP, et al.: Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011; 29(suppl):abstr 10005.
35. Friedrichs N, Kuchler J, Endl E, Koch A, Czerwitzki J, Wurst P, et al.: Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 2008;216:428-39.
36. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S: IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006;25:1042-52. (Pubitemid 43277012)
37. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O: Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 1999;59:3588-91. (Pubitemid 29381857)
38. Maki RG: Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010;28:4985-95.
39. Ayalon D, Glaser T, Werner H: Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11:289-97. (Pubitemid 34257726)
40. Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, Reynolds CP, et al.: Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 1990;86:1806-14.
41. Martins AS, Mackintosh C, Martin DH, Campos M, Hernandez T, Ordonez JL, et al.: Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006; 12:3532-40.
42. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, et al.: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 2008;105:8387-92. (Pubitemid 351904765)
43. Park MS, Ravi V, Araujo DM: Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/ solitary fibrous tumor. Curr Opin Oncol 2010;22:351-5.
44. D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, et al.: Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23:7135-42.
45. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, et al.: Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 2011; 117:4939-47.
46. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, et al.: Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154-60.
47. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al.: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-40.
48. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al.: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32.
49. Van Der Graaf WT, Blay J, Chawla SP, Kim D, Bui Nguyen B, et al.:. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy -an EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011;29(suppl):abstr LBA10002.
50. Di J, Zhang Y, Zheng J Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach. Curr Cancer Drug Targets 2011;Epub ahead of print.
51. Di Cintio A, Di Gennaro E, Budillon A: Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis. Recent Pat Anticancer Drug Discov 2010;5:1-13.
52. Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, et al.: Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 2010;285:10786-96.
53. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, et al.: Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007;67:6626-36. (Pubitemid 47105508)
54. Ito T, Ouchida M, Morimoto Y, Yoshida A, Jitsumori Y, Ozaki T, et al.: Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 2005;224:311-9. (Pubitemid 40725851)
55. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, et al.: Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 2005;116:784-92. (Pubitemid 41099711)
56. Sakimura R, Tanaka K, Yamamoto S, Matsunobu T, Li X, Hanada M, et al.: The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res 2007;13:275-82. (Pubitemid 46121880)